Overview

A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Safety and bioequivalence of SPARC_147709
Phase:
Phase 1
Details
Lead Sponsor:
Sun Pharma Advanced Research Company Limited